patent expiration
The end of a drug's patent protection, after which generics can enter and revenue typically collapses.
As defined in RTW: Investing Across Healthcare
Where it comes up · 1
- RTW: Investing Across Healthcare3 claims
Most important claims · 3 of 3Search all claims for “patent expiration” →
- Over the last decade the big pharma winners were Eli Lilly, up roughly tenfold, Novo Nordisk, up roughly sevenfold, then AbbVie and Merck, while Pfizer, Bristol-Myers, Novartis, Roche and Sanofi have basically gone nowhere, because of product cycles ending and patent expirations.RTW: Investing Across Healthcare
- Eli Lilly and Novo Nordisk have together created roughly $1 trillion in market value by addressing obesity, but this value is temporary because it will shrink back toward zero when Ozempic's patents expire in about 15 years, unlike Microsoft's long-lived franchise.RTW: Investing Across Healthcare
- The industry is entering a period of many large-company patent expirations, so M&A should increase and is starting to, which tends to be bullish for small companies.RTW: Investing Across Healthcare